Kathy is a highly experienced drug discovery scientist with over 25 years of industrial experience gained at SmithKline Beecham and AstraZeneca. Kathy researches and designs bespoke assays that support client’s projects. She has a strong focus on data delivery and assay quality control.

Qualifications.

After gaining a B.Sc. in Biochemistry from the University of Bath in 1989, Kathy joined SmithKline Beecham (SKB) as a research scientist, initially in the rheumatoid arthritis therapy area, and soon generated significant experience in disease models. A move to the CNS disease area led to the opportunity for further study and she gained a Masters in Neuropharmacology whilst still working for SKB.

Specialisms.

Looking for new challenges, Kathy joined AstraZeneca in 2000, working in the Hit Discovery section, developing assays and running high throughput screens for the respiratory and inflammatory disease area. Kathy led the implementation and automation of label-free cell-based screening (on the Epic system from Corning) within AstraZeneca. In 2011, with Gary Allenby, Kathy founded and established Aurelia Bioscience as a preclinical CRO in order to bring their expertise in technology to the biotechnology and pharma sectors. Aurelia BioScience was acquired by Charnwood Molecular in 2021, where Kathy is responsible for the day to day operational leadership of our in-house Biology team and to apply her years of drug discovery experience to our client projects.